Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study

Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study

<p><strong>Purpose:</strong> Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by magrolimab promotes macrophage-mediated phagocytosis of tumor cells and is...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Sallman, DA, Al Malki, MM, Asch, AS, Wang, ES, Jurcic, JG, Bradley, TJ, Flinn, IW, Pollyea, DA, Kambhampati, S, Tanaka, TN, Zeidner, JF, Garcia-Manero, G, Jeyakumar, D, Komrokji, R, Lancet, J, Kantarjian, HM, Gu, L, Zhang, Y, Tan, A, Chao, M, O'Hear, C, Ramsingh, G, Lal, I, Vyas, P, Daver, NG
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	American Society of Clinical Oncology 2023

Παρόμοια τεκμήρια

Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes: 5F9005 phase 1b study results
ανά: Sallman, DA, κ.ά.
Έκδοση: (2022)

MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results
ανά: Sallman, D, κ.ά.
Έκδοση: (2022)

Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase ib results
ανά: Daver, NG, κ.ά.
Έκδοση: (2023)

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS
ανά: D. A. Sallman, κ.ά.
Έκδοση: (2022-06-01)

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results
ανά: Daver, NG, κ.ά.
Έκδοση: (2022)

The first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results
ανά: Sallman, D, κ.ά.
Έκδοση: (2021)

AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results
ανά: Daver, N, κ.ά.
Έκδοση: (2022)

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
ανά: N. G. Daver, κ.ά.
Έκδοση: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
ανά: Garcia-Manero, G, κ.ά.
Έκδοση: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
ανά: Garcia-Manero, G, κ.ά.
Έκδοση: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
ανά: Garcia-Manero, G, κ.ά.
Έκδοση: (2021)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
ανά: Garcia-Manero, G, κ.ά.
Έκδοση: (2021)

A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia
ανά: Daver, N, κ.ά.
Έκδοση: (2021)

A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia
ανά: Daver, N, κ.ά.
Έκδοση: (2022)

A phase 3, randomized trial of magrolimab in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia ineligible for intensive chemotherapy (ENHANCE-3)
ανά: Daver, N, κ.ά.
Έκδοση: (2022)

P551: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53-MUTANT ACUTE MYELOID LEUKEMIA
ανά: N. G. Daver, κ.ά.
Έκδοση: (2022-06-01)

P550: A PHASE 3, RANDOMIZED TRIAL OF MAGROLIMAB IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (ENHANCE-3)
ανά: N. G. Daver, κ.ά.
Έκδοση: (2022-06-01)

A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia
ανά: Vyas, P, κ.ά.
Έκδοση: (2021)

AML-399 A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia (AML)
ανά: Vyas, P, κ.ά.
Έκδοση: (2022)

P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS)
ανά: J. Y. Chen, κ.ά.
Έκδοση: (2022-06-01)

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)
ανά: Chen, J, κ.ά.
Έκδοση: (2022)

P553: A PHASE 2, OPEN-LABEL, MULTIARM, MULTICENTER STUDY TO EVALUATE MAGROLIMAB COMBINED WITH ANTILEUKEMIA THERAPIES FOR FIRST-LINE, RELAPSED/REFRACTORY, OR MAINTENANCE TREATMENT OF ACUTE MYELOID LEUKEMIA
ανά: P. Vyas, κ.ά.
Έκδοση: (2022-06-01)

P699: MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
ανά: Lisa Johnson, κ.ά.
Έκδοση: (2023-08-01)

Karl Popper : critical assessments of leading philosophers /
ανά: O'Hear, Anthony
Έκδοση: (2004)

Philosophy, biology and life /
ανά: O'Hear, Anthony
Έκδοση: (2005)

P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS
ανά: S. P. Desikan, κ.ά.
Έκδοση: (2022-06-01)

Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab
ανά: Fadi Haddad, κ.ά.
Έκδοση: (2021-05-01)

Passions and the Emotions /
ανά: O'Hear, Anthony, editor
Έκδοση: (2019)

PB1888: TRIAL IN PROGRESS: PHASE 1B/2 STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) IN COMBINATION WITH VENETOCLAX/AZACITIDINE OR MAGROLIMAB FOR PATIENTS WITH CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)
ανά: Naval Daver, κ.ά.
Έκδοση: (2023-08-01)

Real-world effectiveness of azacitidine in treatment-naive patients with higher-risk myelodysplastic syndromes
ανά: Rajakumaraswamy, N, κ.ά.
Έκδοση: (2023)

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
ανά: Lachowiez, CA, κ.ά.
Έκδοση: (2022)

AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies
ανά: Lachowiez, C, κ.ά.
Έκδοση: (2022)

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies
ανά: Lachowiez, CA, κ.ά.
Έκδοση: (2021)

Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
ανά: Bruno C. Medeiros, κ.ά.
Έκδοση: (2018-01-01)

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies
ανά: Lachowiez, CA, κ.ά.
Έκδοση: (2023)

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
ανά: David A. Sallman
Έκδοση: (2020-06-01)

698 Safety and tolerability of magrolimab in combination with taxanes in patients with solid tumors
ανά: Rohit Joshi, κ.ά.
Έκδοση: (2023-11-01)

524 A phase 2, multi-arm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors
ανά: Vivek Subbiah, κ.ά.
Έκδοση: (2021-11-01)

Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis
ανά: Ambuj Kumar, κ.ά.
Έκδοση: (2010-02-01)

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS
ανά: N. Rajakumaraswamy, κ.ά.
Έκδοση: (2022-06-01)